Abstract:Parkinson's disease (PD) is a chronic progressive neurodegenerative disorder symptomatically characterized by resting tremor, rigidity, bradykinesia and gait impairment. These motor deficits suffered by PD patients primarily result from selective dysfunction or loss of dopaminergic neurons of the substantia nigra pars compacta (SNpc). Most of the existing therapies for PD are based on the replacement of dopamine, which is symptomatically effective in the early stage but becomes increasingly less effective and is accompanied by serious side effects in the advanced stages of the disease. Currently, there are no strategies to slow neuronal degeneration or prevent the progression of PD. Thus, the prospect of regenerating functional dopaminergic neurons is very attractive. Over the last few decades, significant progress has been made in the development of dopaminergic regenerative strategies for curing PD. The most promising approach seems to be cell-replacement therapy (CRT) using human embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), which are unlimitedly available and have gained much success in preclinical trials. Despite the challenges, stem cell-based CRT will make significant steps toward the clinic in the coming decade. Alternatively, direct lineage reprogramming, especially in situ direct conversion of glia cells to induced neurons, which exhibits some advantages including no ethical concerns, no risk of neoplasia, and even no need for transplantation, has gained much attention recently. Evoking the endogenous regeneration ability of neural stem cells (NSCs) is an idyllic method of dopaminergic neuroregeneration which remains highly controversial. Here, we review many of these advances, highlighting areas and strategies that might be particularly suited to the development of regenerative approaches that restore dopaminergic function in PD. Key words: Parkinson's disease, dopaminergic neurons, embryonic stem cell, induced pluripotent stem cell, neural stem cell, direct lineage reprogramming, endogenous regeneration.

Overcoming challenges of clinical cell therapies for Parkinson's disease with photobiomodulation

Photobiomodulation for Parkinson's Disease in Animal Models: A Systematic Review

Mitochondrial Dysfunction and Parkinson’s Disease—Near-Infrared Photobiomodulation as a Potential Therapeutic Strategy

Brain photobiomodulation therapy on neurological and psychological diseases

Photobiomodulation Therapy on Brain: Pioneering an Innovative Approach to Revolutionize Cognitive Dynamics

Recent Advances in Photobiomodulation Therapy for Brain Diseases

Cell Therapy for Parkinson's Disease

Redefining Parkinson’s Disease Research Using Induced Pluripotent Stem Cells

Photobiomodulation combination therapy as a new insight in neurological disorders: a comprehensive systematic review

Clinical Considerations in Parkinson’s Disease Cell Therapy

Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson’s Disease

Improvements in clinical signs and symptoms of Parkinson's disease using photobiomodulation: a five-year follow-up

Overcoming Methodological Challenges for Advancing Stem Cell Therapies in Parkinson's Disease

Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease.

Phototherapy for age-related brain diseases: challenges, successes and future

Improving treatment for Parkinson's disease: Harnessing photothermal and phagocytosis-driven delivery of levodopa nanocarriers across the blood-brain barrier

Progress in dopaminergic cell-replacement and regenerative strategies for Parkinson's disease.

A Compendium of Preparation and Application of Stem Cells in Parkinson's Disease: Current Status and Future Prospects

Photobiomodulation as a Potential Treatment for Alzheimer's Disease: A Review Paper

Photobiomodulation in experimental models of Alzheimer's disease: state-of-the-art and translational perspectives

Stem Cell Therapy for the Treatment of Parkinson's Disease: What Promise Does it Hold?